ISSN 1671-5411 CN 11-5329/R

Dear Colleagues,

Journal of Geriatric Cardiology (J Geriatr Cardiol, JGC) will launch a new website and adopt ScholarOne ManuscriptsTM system to manage the submission and peer review process from November 1, 2020. To review and check the status of your manuscripts submitted before November 2020, please visit...

more

Volume 17 Issue 11
Dec.  2020
Turn off MathJax
Article Contents
Michael A Chen. Geriatric issues in patients with or being considered for implanted cardiac rhythm devices: a case-based review. J Geriatr Cardiol 2020; 17(11): 710-722. doi: 10.11909/j.issn.1671-5411.2020.11.009
Citation: Michael A Chen. Geriatric issues in patients with or being considered for implanted cardiac rhythm devices: a case-based review. J Geriatr Cardiol 2020; 17(11): 710-722. doi: 10.11909/j.issn.1671-5411.2020.11.009

Geriatric issues in patients with or being considered for implanted cardiac rhythm devices: a case-based review

doi: 10.11909/j.issn.1671-5411.2020.11.009
More Information
  • loading
  • [1]
    Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: A report from the American Heart Association. Circulation 2020; 141: E139-E596.
    [2]
    Curtis AB, Karki R, Hattoum A, et al. Arrhythmias in patients ≥ 80 years of age: pathophysiology, management, and outcomes. J Am Coll Cardiol 2018; 71: 2041-2057. doi: 10.1016/j.jacc.2018.03.019
    [3]
    Kramer DB, Habtemariam D, Adjei-Poku Y, et al. The Decisions, Interventions, and Goals in ImplaNtable Cardioverter- DefIbrillator TherapY (DIGNITY) Pilot Study. J Am Heart Assoc 2017; 6: e006881.
    [4]
    Westerdahl AK, Sjöblom J, Mattiasson AC, et al. Implantable cardioverter-defibrillator therapy before death: High risk for painful shocks at end of life. Circulation 2014; 129: 422-429. doi: 10.1161/CIRCULATIONAHA.113.002648
    [5]
    Medicare decision memo for implanted cardioverter-defibrillators (CAG-00157R4). Available at: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=288 (accessed 11/23/2020).
    [6]
    A decision aid for patients considering ICD therapy for primary prevention. Available at: https:patientdecisionaid.org/icd/ (accessed 11/23/2020).
    [7]
    Kramer DB, Mitchell SL, Brock DW. Deactivation of pacemakers and implantable cardioverter-defibrillators. Prog Cardiovasc Dis 2012; 55: 290-299. doi: 10.1016/j.pcad.2012.09.003
    [8]
    Lampert R, Hayes DL, Annas GJ, et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. This document was developed in collaboration and endorsed by the American Colleg. Hear Rhythm 2010; 7: 1008-1026. doi: 10.1016/j.hrthm.2010.04.033
    [9]
    Pellegrino ED. Decisions to withdraw life-sustaining treatment: A moral algorithm. J Am Med Assoc 2000; 283: 1065-1067. doi: 10.1001/jama.283.8.1065
    [10]
    Rhymes JA, McCullough LB, Luchi RJ, et al. Withdrawing very low-burden interventions in chronically ill patients. J Am Med Assoc 2000; 283: 1061-1063. doi: 10.1001/jama.283.8.1061
    [11]
    Annas GJ. "Culture of Life" Politics at the Bedside-The Case of Terri Schiavo. N Engl J Med 2005; 352: 1710-1715. doi: 10.1056/NEJMlim050643
    [12]
    Quill TE, Barold SS, Sussman BL. Discontinuing an implantable cardioverter defibrillator as a life-sustaining treatment. Am J Cardiol 1994; 74: 205-207. doi: 10.1016/0002-9149(94)90107-4
    [13]
    Pitcher D, Soar J, Hogg K, et al. Cardiovascular implanted electronic devices in people towards the end of life, during cardiopulmonary resuscitation and after death: guidance from the Resuscitation Council (UK), British Cardiovascular Society and National Council for Palliative Care. Heart 2016; 102: A1-A17.
    [14]
    Wilkoff BL, Auricchio A, Brugada J, et al. HRS/EHRA expert consensus on the monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of techniques, indications, personnel, frequency and ethical considerations - Developed in partnership with the Heart Rhythm Society (HRS) an. Europace 2008; 10: 707-725. doi: 10.1093/europace/eun122
    [15]
    2019 Alzheimer's disease facts and figures. Alzheimer's Dement 2019; 15: 321-387.
    [16]
    Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982; 215: 1237-1239. doi: 10.1126/science.7058341
    [17]
    Colovic MB, Krstic DZ, Lazarevic-Pasti TD, et al. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 2013; 11: 315-335. doi: 10.2174/1570159X11311030006
    [18]
    Hernandez RK, Farwell W, Cantor MD, et al. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs New England healthcare system. J Am Geriatr Soc 2009; 57: 1997-2003. doi: 10.1111/j.1532-5415.2009.02488.x
    [19]
    Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study. Arch Intern Med 2009; 169: 867-873. doi: 10.1001/archinternmed.2009.43
    [20]
    Kim DH, Brown RT, Ding EL, et al. Dementia medications and risk of falls, syncope, and related adverse events: Meta- analysis of randomized controlled trials. J Am Geriatr Soc 2011; 59: 1019-1031. doi: 10.1111/j.1532-5415.2011.03450.x
    [21]
    Rowland JP, Rigby J, Harper AC, et al. Cardiovascular monitoring with acetylcholinesterase inhibitors: A clinical protocol. Adv Psychiatr Treat 2007; 13: 178-184. doi: 10.1192/apt.bp.106.002725
    [22]
    Tavassoli N, Sommet A, Lapeyre-Mestre M, et al. Drug interactions with cholinesterase inhibitors: An analysis of the French Pharmacovigilance Database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf 2007; 30: 1063-1071. doi: 10.2165/00002018-200730110-00005
    [23]
    Mohammad D, Chan P, Bradley J, et al. Acetylcholinesterase inhibitors for treating dementia symptoms-a safety evaluation. Expert Opin Drug Saf Taylor & Francis 2017; 16: 1009-1019.
    [24]
    O'Regan J, Lanctôt KL, Mazereeuw G, et al. Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: A meta-analysis of randomized controlled trials. J Clin Psychiatry 2015; 76: e1424-e1431. doi: 10.4088/JCP.14r09237
    [25]
    Krahn AD, Connolly SJ, Roberts RS, et al. Diminishing proportional risk of sudden death with advancing age: Implications for prevention of sudden death. Am Heart J 2004; 147: 837-840. doi: 10.1016/j.ahj.2003.12.017
    [26]
    Kim C, Becker L, Eisenberg MS. Out-of-hospital cardiac arrest in octogenarians and nonagenarians. Arch Intern Med 2000; 160: 3439-3443. doi: 10.1001/archinte.160.22.3439
    [27]
    Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation 2018; 138: e272-e391.
    [28]
    Kremers MS, Hammill SC, Berul CI, et al. The National ICD Registry Report: Version 2.1 including leads and pediatrics for years 2010 and 2011. Hear Rhythm 2013; 10: e59-e65. doi: 10.1016/j.hrthm.2013.01.035
    [29]
    Yung D, Birnie D, Dorian P, et al. Survival after implantable cardioverter-defibrillator implantation in the elderly. Circulation 2013; 127: 2383-2392. doi: 10.1161/CIRCULATIONAHA.113.001442
    [30]
    Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation 2018; 138: e392-e414.
    [31]
    Hess PL, Al-Khatib SM, Han JY, et al. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? an analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes 2015; 8: 179-186. doi: 10.1161/CIRCOUTCOMES.114.001306
    [32]
    Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 375: 1221-1230. doi: 10.1056/NEJMoa1608029
    [33]
    Swindle JP, Rich MW, McCann P, et al. Implantable cardiac device procedures in older patients: Use and in-hospital outcomes. Arch Intern Med 2010; 170: 631-637.
    [34]
    Armaganijan L V., Toff WD, Nielsen JC, et al. Are elderly patients at increased risk of complications following pacemaker implantation? A meta-analysis of randomized trials. PACE - Pacing Clin Electrophysiol 2012; 35: 131-134. doi: 10.1111/j.1540-8159.2011.03240.x
    [35]
    Tsai V, Goldstein MK, Hsia HH, et al. Influence of age on perioperative complications among patients undergoing implantable cardioverter-defibrillators for primary prevention in the united states. Circ Cardiovasc Qual Outcomes 2011; 4: 549-556.
    [36]
    Eberhardt F, Bode F, Bonnemeier H, et al. Long term complications in single and dual chamber pacing are influenced by surgical experience and patient morbidity. Heart 2005; 91: 500-506. doi: 10.1136/hrt.2003.025411
    [37]
    Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations: An analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014; 35: 1186-1194. doi: 10.1093/eurheartj/eht511
    [38]
    Koplan BA, Epstein LM, Albert CM, et al. Survival in octogenarians receiving implantable defibrillators. Am Heart J 2006; 152: 714-719. doi: 10.1016/j.ahj.2006.06.008
    [39]
    Ertel D, Phatak K, Makati K, et al. Predictors of early mortality in patients age 80 and older receiving implantable defibrillators. PACE - Pacing Clin Electrophysiol 2010; 33: 981-987.
    [40]
    Fudim M, Parzynski CS, Pokorney SD, et al. Periprocedural risk and survival after ICD placement in patients with advanced heart failure. J Card Fail 2018; 24: S63.
    [41]
    Friedman DJ, Al-Khatib SM, Zeitler EP, et al. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. Am Heart J 2017; 191: 21-29. doi: 10.1016/j.ahj.2017.06.002
    [42]
    Green AR, Leff B, Wang Y, et al. Geriatric conditions in patients undergoing defibrillator implantation for prevention of sudden cardiac death: prevalence and impact on mortality. Circ Cardiovasc Qual Outcomes 2016; 9: 23-30. doi: 10.1161/CIRCOUTCOMES.115.002053
    [43]
    Barsheshet A, Wang PJ, Moss AJ, et al. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT- CRT (Multicenter Automatic Defibrillator Implantation TrialCardiac Resynchronization Therapy). J Am Coll Cardiol 2011; 57: 2416-2423. doi: 10.1016/j.jacc.2010.12.041
    [44]
    Killu AM, Wu JH, Friedman PA, et al. Outcomes of cardiac resynchronization therapy in the elderly. PACE - Pacing Clin Electrophysiol 2013; 36: 664-672. doi: 10.1111/pace.12048
    [45]
    Achilli A, Turreni F, Gasparini M, et al. Efficacy of cardiac resynchronization therapy in very old patients: The insync/ insync ICD Italian registry. Europace 2007; 9: 732-738. doi: 10.1093/europace/eum143
    [46]
    Lund LH, Benson L, Ståhlberg M, et al. Age, prognostic impact of QRS prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: Findings from 14-713 patients in the Swedish Heart Failure Registry. Eur J Heart Fail 2014; 16: 1073-1081. doi: 10.1002/ejhf.162
    [47]
    Lee MY, Yeshwant SC, Chava S, et al. Mechanisms of heart block after transcatheter aortic valve replacement -cardiac anatomy, clinical predictors and mechanical factors that contribute to permanent pacemaker implantation. Arrhythmia Electrophysiol Rev 2015; 4: 81-85. doi: 10.15420/AER.2015.04.02.81
    [48]
    Baan J, Yong ZY, Koch KT, et al. Factors associated with cardiac conduction disorders and permanent pacemaker implantation after percutaneous aortic valve implantation with the CoreValve prosthesis. Am Heart J 2010; 159: 497-503. doi: 10.1016/j.ahj.2009.12.009
    [49]
    Holmes DR, Nishimura RA, Grover FL, et al. Annual outcomes with transcatheter valve therapy from the STS/ACC TVT Registry. J Am Coll Cardiol 2015; 66: 2813-2823. doi: 10.1016/j.jacc.2015.10.021
    [50]
    Koos R, Mahnken AH, Aktug Ö, et al. Electrocardiographic and imaging predictors for permanent pacemaker requirement after transcatheter aortic valve implantation. J Heart Valve Dis 2011; 20: 83-90.
    [51]
    Holmes DR, MacK MJ, Kaul S, et al. 2012 ACCF/AATS/ SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 2012; 59: 1200-1254. doi: 10.1016/j.jacc.2012.01.001
    [52]
    Zahn R, Gerckens U, Grube E, et al. Transcatheter aortic valve implantation: First results from a multi-centre real-world registry. Eur Heart J 2011; 32: 198-204. doi: 10.1093/eurheartj/ehq339
    [53]
    Binder RK, Webb JG, Toggweiler S, et al. Impact of post-implant SAPIEN XT geometry and position on conduction disturbances, hemodynamic performance, and paravalvular regurgitation. JACC Cardiovasc Interv 2013; 6: 462-468. doi: 10.1016/j.jcin.2012.12.128
    [54]
    Al-Ogaili A, Fugar S, Okoh A, et al. Trends in complete heart block after transcatheter aortic valve replacement: A population based analysis. Catheter Cardiovasc Interv 2019; 94: 773-780. doi: 10.1002/ccd.28156
    [55]
    Regueiro A, Altisent OAJ, Trigo M Del, et al. Impact of new-onset left bundle branch block and periprocedural permanent pacemaker implantation on clinical outcomes in patients undergoing transcatheter aortic valve replacement. Circ Cardiovasc Interv 2016; 9: e003635. doi: 10.1161/CIRCINTERVENTIONS.115.003635
    [56]
    Mouillet G, Lellouche N, Yamamoto M, et al. Outcomes following pacemaker implantation after transcatheter aortic valve implantation with CoreValveⓇ devices: Results from the France 2 Registry. Catheter Cardiovasc Interv 2015; 86: E158-E166. doi: 10.1002/ccd.25818
    [57]
    Webb JG, Dvir D. Transcatheter aortic valve replacement for bioprosthetic aortic valve failure: The valve-in-valve procedure. Circulation 2013; 127: 2542-2550. doi: 10.1161/CIRCULATIONAHA.113.000631
    [58]
    Boon RMA Van Der, Mieghem NM Van, Theuns DA, et al. Pacemaker dependency after transcatheter aortic valve implantation with the self-expanding medtronic core valve system. Int J Cardiol 2013; 168: 1269-1273. doi: 10.1016/j.ijcard.2012.11.115
    [59]
    Ream K, Sandhu A, Valle J, et al. Ambulatory rhythm monitoring to detect late high-grade atrioventricular block following transcatheter aortic valve replacement. J Am Coll Cardiol 2019; 73: 2538-2547.
    [60]
    El-Chami MF, Al-Samadi F, Clementy N, et al. Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical control. Hear Rhythm 2018; 15: 1800-1807. doi: 10.1016/j.hrthm.2018.08.005
    [61]
    Merkel M, Grotherr P, Radzewitz A, et al. Leadless pacing: current state and future direction. Cardiol Ther 2017; 6: 175-181. doi: 10.1007/s40119-017-0097-3
    [62]
    Tachibana M, Banba K, Matsumoto K, et al. The feasibility of leadless pacemaker implantation for superelderly patients. Pacing Clin Electrophysiol 2020; 43: 374-381. doi: 10.1111/pace.13894
    [63]
    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American college of Cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 2014; 64: e1-e76. doi: 10.1016/j.jacc.2014.03.022
    [64]
    Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis. Circulation 2000; 101: 1138-1144. doi: 10.1161/01.CIR.101.10.1138
    [65]
    Brown CS, Mills RM, Conti JB, et al. Clinical improvement after atrioventricular nodal ablation for atrial fibrillation does not correlate with improved ejection fraction. Am J Cardiol 1997; 80: 1090-1091. doi: 10.1016/S0002-9149(97)00612-7
    [66]
    Vergara G. Long-term survival after ablation of atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. Ital Heart J 2001; 2: 1243-1245.
    [67]
    Marshall HJ, Harris ZI, Griffith MJ, et al. Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: Effects of pacing mode and mode- switch algorithm. Circulation 1999; 99: 1587-1592. doi: 10.1161/01.CIR.99.12.1587
    [68]
    Kamalvand K, Tan K, Kotsakis A, et al. Is mode switching beneficial? A randomized study in patients with paroxysmal atrial tachyarrhythmias. J Am Coll Cardiol 1997; 30: 496-504. doi: 10.1016/S0735-1097(97)00162-9
    [69]
    Vernooy K, Dijkman B, Cheriex EC, et al. Ventricular remodeling during long-term right ventricular pacing following his bundle ablation. Am J Cardiol 2006; 97: 1223-1227. doi: 10.1016/j.amjcard.2005.11.044
    [70]
    Tops LF, Schalij MJ, Holman ER, et al. Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. J Am Coll Cardiol 2006; 48: 1642-1648.
    [71]
    Leon AR, Greenberg JM, Kanuru N, et al. Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: Effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol 2002; 39: 1258-1263. doi: 10.1016/S0735-1097(02)01779-5
    [72]
    Doshi RN, Daoud EG, Fellows C, et al. Left ventricular- based cardiac stimulation post AV nodal ablation evaluation (The PAVE study). J Cardiovasc Electrophysiol 2005; 16: 1160-1165. doi: 10.1111/j.1540-8167.2005.50062.x
    [73]
    Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013; 368: 1585-1593. doi: 10.1056/NEJMoa1210356
    [74]
    Gasparini M, Auricchio A, Metra M, et al. Long-term survival in patients undergoing cardiac resynchronization therapy: The importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 2008; 29: 1644-1652. doi: 10.1093/eurheartj/ehn133
    [75]
    Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/ HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American college of cardiology foundation/American heart association task force on practice guide. J Am Coll Cardiol 2012; 60: 1297-1313. doi: 10.1016/j.jacc.2012.07.009
    [76]
    Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2013; 62: 62: e147-e239 doi: 10.1016/j.jacc.2013.05.019
    [77]
    Ozcan C, Jahangir A, Friedman PA, et al. Sudden death after radiofrequency ablation of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol 2002; 40: 105-110. doi: 10.1016/S0735-1097(02)01927-7
    [78]
    Hamdan MH, Page RL, Sheehan CJ, et al. Increased sympathetic activity after atrioventricular junction ablation in patients with chronic atrial fibrillation. J Am Coll Cardiol 2000; 36: 151-158. doi: 10.1016/S0735-1097(00)00699-9
    [79]
    Silva RMFL da. Syncope: Epidemiology, etiology, and prognosis. Front Physiol 2014; 5: 471.
    [80]
    Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009; 30: 2631-2671. doi: 10.1093/eurheartj/ehp298
    [81]
    Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/ HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2017; 70: e39-e110. doi: 10.1016/j.jacc.2017.03.003
    [82]
    Santini M, Castro A, Giada F, et al. Prevention of syncope through permanent cardiac pacing in patients with bifascicular block and syncope of unexplained origin: The PRESS study. Circ Arrhythmia Electrophysiol 2013; 6: 101-107. doi: 10.1161/CIRCEP.112.975102
    [83]
    Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: The PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv 2015; 8: 60-69.
    [84]
    Siontis GCM, Jüni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: A meta-analysis. J Am Coll Cardiol 2014; 64: 129-140. doi: 10.1016/j.jacc.2014.04.033
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Article Metrics

    Article views (98) PDF downloads(8) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return